Previous 10 | Next 10 |
Vir Biotechnology (NASDAQ: VIR) isn't first to cross the finish line with its antibody treatment for COVID-19. In fact, with its recent Emergency Use Authorization (EUA), it joins two much bigger players. The U.S. Food and Drug Administration earlier granted EUAs to Eli Lilly an...
Xencor ([[XNCR]] -0.2%) is expected to generate “a useful cash windfall in the coming months,” noted SVB Leerink analyst Geoffrey Porges in reaction to the FDA’s emergency use authorization granted for a COVID-19 therapy developed by GlaxoSmithKline ([[GSK]] -1....
Vir Biotechnology Inc ( NASDAQ: VIR ) shares jumped roughly 10% in after-hours trading on Wednesday as the company received emergency use authorisation for its COVID-19 drug from the U.S Food and Drug Administration (FDA). The federal agency’s approval for Sotrovimab (VIR...
Vertex Energy (VTNR) +98% on deal for Shell's Mobile refinery.Moxian (MOXC) +37%.1847 Goedeker (GOED) +22%.SOS Limited (SOS) +14%.Bit Digital (BTBT) +13%.Vir Biotechnology (VIR) +9% as GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization.LAIX (LAIX) +12% on Q1 results...
The FDA has granted Emergency Use Authorization ("EUA") to sotrovimab, a monoclonal antibody from GlaxoSmithKline (GSK) and Vir Biotechnology (VIR), for mild-to-moderate COVID-19.The approval is in people 12 years of age and older who are at high risk of developing severe COVID-19, inclu...
– Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial – – In vitro data indicate sotrovimab maintains activ...
– Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion when making n...
GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announce that the EMA's Committee for Human Medicinal Products ((CHMP)) has issued a positive opinion relating to the use of sotrovimab for the treatment of adults and adolescents with COVID-19 who do not require oxygen supplementation an...
– Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion when making n...
Palm Beach, FL – May 20, 2021 – In the race against emerging coronavirus variants, researchers are looking beyond antibodies for clues to lasting protection from COVID-19. Concerns about coronavirus variants that might be partially resistant to antibody defenses have spurred r...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...